|
|
 Previous Article | Table of Contents | Next Article 
2-Chlorodeoxyadenosine: an effective new agent for the treatment of chronic
lymphocytic leukemia
LD Piro, CJ Carrera, E Beutler and DA Carson
Department of Basic and Clinical Research, Scripps Clinic, La Jolla, CA
92037.
2-Chlorodeoxyadenosine, a new lymphocyte-selective, anti-neoplastic drug
was administered to 18 patients with advanced chronic lymphocytic leukemia
of B-cell origin. All patients were resistant to conventional treatment. A
total of 44 courses of 2-chlorodeoxyadenosine were completed with minimal
toxicity. An overall response rate of 55% was achieved with four of 18
patients demonstrating partial response and six of 18 patients experiencing
clinical improvement. Only minor bone marrow suppression occurred during
administration of the drug, indicating a high degree of lymphocyte
selectivity. Reduction of lymphocyte infiltration in bone marrow occurred
in treated patients including one patient who experienced normalization of
the bone marrow. Three of four patients with concurrent autoimmune
hemolytic anemia experienced resolution of hemolysis, as indicated by
elimination of transfusion requirement, fall in reticulocyte count,
elevation of hemoglobin, and ability to taper prednisone without recurrence
of hemolysis. Duration of responses ranged from 2 to 15 months without
maintenance therapy.
Volume 72,
Issue 3,
pp. 1069-1073,
09/01/1988
Copyright © 1988 by The American Society of Hematology
 CiteULike  Connotea  Del.icio.us  Digg  Reddit  Technorati What's this?
This article has been cited by other articles:
|
|
|
|
 
V. A. Morrison
Management of Infectious Complications in Patients with Chronic Lymphocytic Leukemia
Hematology,
January 1, 2007;
2007(1):
332 - 338.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. G. Gribben
Salvage Therapy for CLL and the Role of Stem Cell Transplantation
Hematology,
January 1, 2005;
2005(1):
292 - 298.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
V. Gandhi, W. Plunkett, S. Weller, M. Du, M. Ayres, C. O. Rodriguez Jr, P. Ramakrishna, G. L. Rosner, J. P. Hodge, S. O'Brien, et al.
Evaluation of the Combination of Nelarabine and Fludarabine in Leukemias: Clinical Response, Pharmacokinetics, and Pharmacodynamics in Leukemia Cells
J. Clin. Oncol.,
April 15, 2001;
19(8):
2142 - 2152.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
K. Lotfi, E. Mansson, T. Spasokoukotskaja, B. Pettersson, J. Liliemark, C. Peterson, S. Eriksson, and F. Albertioni
Biochemical Pharmacology and Resistance to 2-Chloro-2'-arabino-fluoro-2'-deoxyadenosine, a Novel Analogue of Cladribine in Human Leukemic Cells
Clin. Cancer Res.,
September 1, 1999;
5(9):
2438 - 2444.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. K Morris, J. M Kolesar, and J. G Kuhn
Review : Purine nucleoside analogs: fludarabine, entostatin and cladribine: Part 3: cladribine
Journal of Oncology Pharmacy Practice,
June 1, 1997;
3(2):
94 - 109.
[PDF]
|
|
|
|
|
|
|
P. Fidias, B. A. Chabner, and M. L. Grossbard
Purine Analogs for the Treatment of Low-Grade Lymphoproliferative Disorders
Oncologist,
June 1, 1996;
1(3):
125 - 139.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
S. O'Brien, H. Kantarjian, E. Estey, C. Koller, B. Robertson, M. Beran, M. Andreeff, S. Pierce, and M. Keating
Lack of Effect of 2-Chlorodeoxyadenosine Therapy in Patients with Chronic Lymphocytic Leukemia Refractory to Fludarabine Therapy
N. Engl. J. Med.,
February 3, 1994;
330(5):
319 - 322.
[Abstract]
[Full Text]
|
|
|
|
|
|
|
E. J. Dann, S. Gillis, A. Polliack, E. Okon, D. Rund, and E. A. Rachmilewitz
Tumor Lysis Syndrome Following Treatment with 2-Chlorodeoxyadenosine for Refractory Chronic Lymphocytic Leukemia
N. Engl. J. Med.,
November 18, 1993;
329(21):
1547 - 1548.
[Full Text]
|
|
|
|
|
|
|
D. L. Betcher and N. Burnham
2-Chlorodeoxyadenosine
Journal of Pediatric Oncology Nursing,
January 1, 1992;
9(4):
192 - 193.
[PDF]
|
|
|
|
|
